Aakaar Medical (AAKAAR)

Score breakdown: P/E: 2/3 · ROCE: 2/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• RoCE of 26.66% points to efficient use of capital, if recent losses are temporary
• Promoter holding of 67.05% aligns promoter and public shareholder interests
• Trailing P/E of 14.90 is not excessive based on historical earnings
• Current price is well below the 52-week high of ₹84.95, so expectations are muted

Concerns

• Latest quarter net loss of ₹1 crore against ₹25 crore sales shows earnings deterioration
• Piotroski F-Score of 3/9 indicates weak financial health and possible balance-sheet stress
• Zero sales/profit growth and zero dividend yield offer no reward while waiting
• Book value, P/B, and debt/equity are unavailable, making margin-of-safety calculation impossible

AI Analysis

At ₹56.50, Aakaar Medical is a small personal-care company with a market cap of just ₹90 crore. The trailing P/E of 14.90 looks reasonable, but I have learned that a cheap multiple can be a value trap when earnings deteriorate. The latest quarter reports sales of ₹25 crore and a net loss of ₹1 crore. That is a serious warning sign. Sales growth is zero, profit growth is zero, and the Piotroski F-score is only 3 out of 9. These are not the numbers of a healthy compounding business. I also cannot calculate a conventional margin of safety because book value and debt-equity data are not available. In Graham's language, the absence of data is not comfort; it is a reason to demand more information. Promoter holding is high at 67.05%, which at least suggests owner interests are aligned with minority investors. The 26.66% ROCE is genuinely impressive, if it is sustainable, but current profitability is not proving it. There is no dividend yield, so I am not being paid to wait. The stock has fallen from ₹84.95 to ₹56.50, but a falling price is not automatically an opportunity. For a value investor, the question is whether the underlying business can generate reliable future profits. With a loss in the latest quarter and an F-score of 3, this looks more like a turnaround situation than a stable slow grower. I would want to see several quarters of positive net profit, clearer revenue traction, and full balance-sheet disclosure before committing capital. Until then, the prudent stance is to observe, not own.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer